Amgen expands U.S. manufacturing footprint, BioNTech scales back capacity: biopharmaceutical manufacturing strategies diverge more rapidly

Amgen Expands U.S. Manufacturing Footprint, BioNTech Reduces Capacity: Divergence in Biopharmaceutical Manufacturing Strategies Accelerates

Introduction

Global biopharmaceutical manufacturing is undergoing a clear rebalancing. The opposite signals sent by Amgen and BioNTech on the same day are almost the most direct illustration of this trend: the former continues to ramp up domestic U.S. capacity, while the latter is shrinking its manufacturing footprint after demand for COVID-19 vaccines has declined, and redirecting resources toward oncology and next-generation mRNA pipelines.

This is not simply a corporate operating move, but a deeper industrial logic behind Digital Health, AI Healthcare, Medical Devices, and Biotech Innovation: whoever controls manufacturing capability is closer to supply chain resilience, cost control, and market access.

Industry Context

Over the past few years, the biopharmaceutical industry rapidly expanded capacity during the pandemic, forming a “high-turnover manufacturing logic” geared toward mRNA vaccines and high-demand biologics. But in the post-pandemic phase, demand patterns, the regulatory environment, and policy expectations are all changing. Companies are beginning to reassess which capacity needs to be retained, which plants need to be consolidated, and which regions are worth continued investment.

Amgen’s additional investment comes against this backdrop. According to the reference information, the company plans to reinvest $300 million in Puerto Rico to expand its biologics manufacturing network. This investment is also part of nearly $2 billion in U.S. manufacturing commitments made over the past year. For large biopharmaceutical companies, manufacturing sites are no longer just cost centers, but competitive barriers: capacity scale, quality systems, delivery stability, and geographic positioning all directly affect product launch timelines and supply reliability.

At the same time, BioNTech’s adjustments reflect another reality. As demand for COVID-19 vaccines continues to decline, and vaccine manufacturing responsibilities increasingly shift to its partner Pfizer, the company is facing excess capacity. It has chosen to close multiple facilities in Idar-Oberstein, Marburg, and Tübingen in Germany, and has completed plans to exit its manufacturing facility in Singapore. This means that manufacturing assets rapidly built during the pandemic are now being “folded back” in line with the new market structure.

Key Developments

Amgen: Continued expansion around U.S.-based manufacturing and supply chain resilience

Amgen’s investment in Puerto Rico continues the trend toward regionalization in pharmaceutical manufacturing. Puerto Rico has long been a production base for major biopharmaceutical companies, with a mature biologics manufacturing ecosystem. For Amgen, continuing to expand capacity locally is both an extension of manufacturing capability and a response to supply chain disruption risks, policy uncertainty, and tariff pressure.Reference information shows that an increasing number of companies in the industry are accelerating manufacturing investment in the United States to hedge against the threat of tariffs on imported drugs and reduce reliance on overseas production. For Biotech Innovation and the biosimilars market, this direction is especially important because complex biologics place higher demands on process consistency, cold chain management, and production line stability; manufacturing capability itself has already become part of product competitiveness.

BioNTech: Scaling Back Pandemic-Era Capacity, Shifting to Oncology and the mRNA Platform

BioNTech’s move looks more like an exit from the pandemic windfall. The company plans to cut about 1,860 jobs, or roughly 22% of its workforce. Closing plants does not mean abandoning manufacturing, but rather shifting from “scaling up for the pandemic” to “reallocating capacity for new pipelines.”

The core of this change lies in the shift in demand structure. Falling COVID-19 vaccine sales mean that the production facilities built for peak demand no longer fully match the current business model. At the same time, the company wants to reduce costs and direct more capital and manpower toward oncology programs and next-generation mRNA therapies.

From an industry perspective, this adjustment also shows that mRNA companies are moving away from single-product drivers toward a more typical innovative drug platform company model: the manufacturing system needs to follow the pipeline, not the other way around.

Market Implications

The contrast between these two companies highlights a growing split in biopharmaceutical manufacturing:

• Companies with diversified commercial portfolios and steadily growing biologics businesses are more inclined to expand domestic manufacturing and regional supply networks.
• Companies that rapidly expanded during the pandemic but later saw demand decline are more likely to restructure by consolidating plants, optimizing costs, and exiting redundant capacity.

For the medtech industry, this change brings at least three implications.

First, manufacturing capability is becoming a key focus of capital allocation. Investment is no longer just a bet on R&D pipelines, but also on capacity layout, automation levels, and quality systems. For equipment vendors, factory digitalization service providers, and manufacturing software providers tied to the biopharmaceutical supply chain, this trend may create new order opportunities.

Second, regionalized production will continue to shape the market landscape. U.S. domestic manufacturing and production hubs such as Puerto Rico may continue to attract new investment in biologics, biosimilars, and critical intermediates. For companies seeking to enter the U.S. market, local production capacity is sometimes not only an operational choice, but also a strategic prerequisite for market access and supply assurance.

Third, manufacturing flexibility will affect the competitive landscape. In the biosimilars market, cost, scale, and the ability to maintain continuous supply are equally critical. Whoever can adjust production lines faster, shorten changeover times, and maintain stable supply will be more likely to gain an edge in a highly competitive market.

Challenges And Risks

Neither expansion nor contraction in manufacturing comes without a cost.For Amgen, continuing to invest in domestic capacity means higher capital expenditures, and it also means ensuring that newly added facilities can maintain high utilization over the coming years. If the policy environment, demand mix, or regulatory requirements change, excessive expansion could likewise create pressure.

For BioNTech, shutting down factories and laying off staff may help ease redundant capacity, but it also brings transition risks. The exit of manufacturing assets, employee placement, and supply chain restructuring could all affect organizational stability. More importantly, the company’s shift from a pandemic-driven manufacturing model to a pipeline-driven model requires rebuilding the alignment between R&D pacing and the production system.

In addition, the entire industry faces a common issue: balancing manufacturing resilience and cost efficiency. Against a backdrop of rising global uncertainty and policies that place greater emphasis on local production, companies must both retain sufficient redundancy and avoid locking capital into low-utilization capacity.

Future Outlook

Over the next 3 to 5 years, biopharmaceutical manufacturing will most likely continue evolving along three directions.

First, investment in local manufacturing in the U.S., Europe, and some Asian markets will continue to increase. Policy, tariffs, supply security, and public opinion are all pushing companies to reconfigure their capacity footprint.

Second, factory digitization and automation will continue to rise. As production complexity increases, AI Healthcare-related quality monitoring, predictive maintenance, production scheduling optimization, and anomaly detection will increasingly be integrated into manufacturing systems. This will not only affect pharmaceutical companies, but also benefit enterprises related to Medical Devices, industrial sensing, pharmaceutical SaaS, and manufacturing execution systems.

Finally, capital will increasingly favor “innovation with manufacturing barriers.” The valuation logic that relies solely on an R&D story is under pressure, while companies that can integrate R&D, capacity, and supply chains may be more likely to attract long-term capital favor.

This trend is especially important for the biosimilars and complex biologics markets. Future competition will not only take place at the clinical and regulatory approval level, but also at the factory, supply chain, and regional layout levels.

Conclusion

The opposing moves by Amgen and BioNTech show that biopharmaceutical manufacturing is shifting from the rapid expansion of the pandemic era toward more refined capacity management and regionalized布局. For the industry, this is not only a strategic adjustment by companies, but also a structural change driven jointly by capital and the regulatory environment. In the future, those who can combine manufacturing efficiency, supply resilience, and technological upgrading will be the ones most likely to take the lead in the new round of restructuring in the healthcare technology industry.